Results 21 to 30 of about 195,924 (307)

Supersensitive PSA-Monitored neoadjuvant hormone treatment of clinically localized prostate cancer: Effects on positive margins, tumor detection and epithelial cells in bone marrow [PDF]

, 1998
Objective: The present study was done to investigate the effects of supersensitive PSA-controlled inductive treatment on positive margins, detection of tumor and epithelial cells in bone marrow of 101 patients with untreated and clinically localized ...
J. Kö, J. Spitz, K. Pantel, M. Kossiwakis, M.W. Kö, Th. Enzmann, U. Feek, U. Kaulfuss, W. Martell   +8 more
core   +1 more source

Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma

npj Breast Cancer, 2021
Neoadjuvant therapy in breast cancer can downstage axillary lymph nodes and reduce extent of axillary surgery. As such, accurate determination of nodal status after neoadjuvant therapy and before surgery impacts surgical management. There are scarce data
Mary Kathryn Abel, Heather Greenwood, Tatiana Kelil, Ruby Guo, Case Brabham, Nola Hylton, Jasmine Wong, Michael Alvarado, Cheryl Ewing, Laura J. Esserman, Judy C. Boughey, Rita A. Mukhtar   +11 more
doaj   +1 more source

Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma

Journal of the National Cancer Center, 2022
: Objective: This is a prospective, single-arm, phase Ib study to evaluate the safety and efficacy of camrelizumab combined with chemotherapy and apatinib as neoadjuvant therapy for locally advanced thoracic esophageal squamous cell carcinoma (ESCC ...
Zhen Wang, Xiankai Chen, Yong Li, Jianjun Qin, Yuan Fang, Zhaoyang Yang, Yan Fang, Dong Qu, Ruixiang Zhang, Qingfeng Zheng, Xiaozheng Kang, Liyan Xue, Jing Huang, Yin Li, Jie He   +14 more
doaj   +1 more source

Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysis

Frontiers in Pharmacology, 2022
Background: Significant survival benefit of adjuvant imatinib therapy has been observed in gastrointestinal stromal tumor (GIST). However, the impact of neoadjuvant imatinib on prognosis of GIST remains unclear.
Zhen Liu, Zimu Zhang, Juan Sun, Jie Li, Ziyang Zeng, Mingwei Ma, Xin Ye, Fan Feng, Weiming Kang   +8 more
doaj   +1 more source

Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

Frontiers in Oncology, 2021
BackgroundImmune checkpoint inhibitors (ICIs) have shown promising anti-tumor activity in multiple malignances including breast cancer. However, the responses can vary.
Yunhai Li, Lei Xing, Fan Li, Hong Liu, Lu Gan, Dejuan Yang, Mengxue Wang, Xuedong Yin, Hongyuan Li, Guosheng Ren, Guosheng Ren   +10 more
doaj   +1 more source

Magnetic resonance imaging tumor regression shrinkage patterns after neoadjuvant chemotherapy in patients with locally advanced breast cancer: correlation with tumor biological subtypes and pathological response after therapy [PDF]

, 2017
The objective of this study is to analyze magnetic resonance imaging shrinkage pattern of tumor regression after neoadjuvant chemotherapy and to evaluate its relationship with biological subtypes and pathological response.
Anastasi, Emanuela, Ballesio, Laura, Catalano, Carlo, DI PASTENA, Francesca, Gigli, Silvia, Giraldi, Guglielmo, Manganaro, Lucia   +6 more
core   +1 more source

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [PDF]

, 2017
Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC ...
Ansari, Bilal, Buyse, Marc E., Conlin, Alison K., Geyer, Charles E., Jr., Gross, Howard M., Jacobs, Samuel A., Keogh, George P., Lord, Raymond S., Mamounas, Eleftherios P., Mauquoi, Celine, Patocskai, Erica J., Polikoff, Jonathan A., Rastogi, Priya, Robidoux, André, Smith, John W., Stella, Philip J., Swain, Sandra M., Wolmark, Norman   +17 more
core   +2 more sources

Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?

Annals of Gastroenterological Surgery, 2020
Although upfront surgery has been the gold standard for pancreatic adenocarcinoma that is planned for resection, it should be compared with the alternative strategy of neoadjuvant therapy.
Fuyuhiko Motoi, Michiaki Unno
doaj   +1 more source

Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. [PDF]

, 2019
Dedicated breast positron emission tomography (dbPET) is an emerging technology with high sensitivity and spatial resolution that enables detection of sub-centimeter lesions and depiction of intratumoral heterogeneity.
Chien, Amy J, Esserman, Laura J, Franc, Benjamin L, Hylton, Nola M, Joe, Bonnie N, Jones, Ella F, Li, Wen, Mukhtar, Rita A, Pampaloni, Miguel H, Ray, Kimberly M, Seo, Youngho   +10 more
core   +2 more sources

The Role of VEGFA, COX2, HUR and CUGBP2 in Predicting the Response to Neoadjuvant Therapy in Rectal Cancer Patients

Medicina, 2020
Background and objectives: The effectiveness of neoadjuvant therapy, which is commonly used for stage II-III rectal cancer (RC) treatment, is limited. Genes associated with the pathogenesis of RC could determine response to this treatment. Therefore, the
Henrikas Pauzas, Ugne Gyvyte, Tadas Latkauskas, Laura Kairevice, Paulius Lizdenis, Saulius Svagzdys, Erika Birgiolaite, Irma Kuliaviene, Juozas Kupcinskas, Algimantas Tamelis   +9 more
doaj   +1 more source